Roivant Sciences Ltd. (ROIV)

Roivant Sciences Ltd. (ROIV) stock has risen significantly over the past six months. In April 2024, positive results from the Phase 2 NEPTUNE study of brepocitinib were announced, and a $1.5 billion share repurchase program was authorized. In August 2025, the company reported financial results for Q1 2025 and noted that the brepocitinib VALOR Phase 3 study was on track. In February 2026, Roivant reported a smaller-than-expected quarterly loss but missed revenue estimates, though the stock surged following positive Phase 2 results for brepocitinib in cutaneous sarcoidosis. Analysts have consistently revised upwards their sales and EPS forecasts, with a consensus recommending "overweighting" or "purchasing" the stock.

The demand for Roivant Sciences Ltd.'s products is primarily driven by medical need, disease prevalence, regulatory approvals, and market access, rather than traditional seasonal patterns.

Roivant Sciences Ltd. is a biopharmaceutical company focused on developing and commercializing medicines and technologies through its "Vant" subsidiaries. The company also incubates discovery-stage companies and health technology startups. Key products and pipeline candidates include Vtama® for plaque psoriasis and atopic dermatitis, Brepocitinib for dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis, IMVT-1402 and Batoclimab for IgG-mediated autoimmune indications, Mosliciguat for pulmonary hypertension, and RVT-2001 for various illnesses.

Roivant Sciences Ltd. is headquartered in London, United Kingdom, with major offices in New York City, Boston, and Basel.

Roivant Sciences Ltd. generally has a positive brand reputation, particularly among financial analysts who have consistently revised sales and EPS forecasts upwards. The consensus rating is a "Moderate Buy" or "Overweight/Purchase," with upward revisions in price targets. Positive clinical trial results contribute to a strong scientific and developmental reputation.

Roivant Sciences Ltd. (ROIV) stock ownership includes institutional, insider, and public/individual investors. As of Q4 2025, institutions held 78.49% of total shares, with major holders including Fmr Llc and Morgan Stanley. Insiders own approximately 21.34% of the stock, with Qvt Financial LP being the largest individual shareholder and Vivek Ramaswamy owning 10.5% of the company.